

---

# TABLE OF CONTENTS

PREFACE.....	V
ACKNOWLEDGMENTS.....	XV
IN MEMORIAM .....	XIX
TABLE OF CASES.....	LXV
<b>Chapter 1. History and Context.....</b>	<b>1</b>
A. Global Precedents .....	1
Peter Barton Hutt, <i>Government Regulation of the Integrity of the Food Supply</i> .....	1
B. The Development of FDA as an Institution .....	3
Peter Barton Hutt, <i>A Historical Introduction</i> .....	3
Richard A. Merrill, <i>The Architecture of Government Regulation of Medical Products</i> .....	5
C. The Development of American Food and Drug Legislation .....	6
1. State and Local Laws in the 19th Century .....	6
2. National Developments Leading up to 1906 .....	7
3. The 1906 Pure Food and Drugs Act .....	9
Lauffer Hayes & Frank Ruff, <i>The Administration of the Federal Food and Drugs Act</i> .....	9
1917 Report of the USDA Bureau of Chemistry .....	10
Note.....	11
4. The Federal Food, Drug, and Cosmetic Act of 1938 .....	11
1933 Report of the Food and Drug Administration .....	11
5. The Growth of the FD&C Act: Amendments Since 1938 .....	12
6. Other Laws Enforced by FDA .....	15
D. FDA's Mission .....	16
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill, 2022 .....	16
Fact Sheet: FDA at a Glance.....	18
Note.....	20
E. FDA's Structure and Organization.....	20
1. Legal Basis for the Agency .....	20
2. The FDA Commissioner.....	20
3. The FDA Chief Counsel .....	21
4. FDA's Place Within the Federal Government.....	21
Peter Barton Hutt, <i>Balanced Government Regulation of Consumer Products</i> .....	23
5. FDA's Size and Internal Organization .....	24
F. FDA's Relationship with Other Agencies.....	26
G. FDA's Relationship with Regulated Industry .....	28
Review Panel on New Drug Regulation, Final Report .....	28
Final Report of the National Committee to Review Procedures for Approval of New Drugs for Cancer and Aids .....	29
Note.....	30

H.	FDA Records: The Freedom of Information Act.....	30
	Peter Barton Hutt, <i>Public Information and Public Participation in the Food and Drug Administration</i> .....	31
	Notes.....	32
I.	FDA Resources.....	33
	Note.....	34
J.	The Regulatory Environment.....	34
<b>Chapter 2. Administrative Law and Procedure at FDA.....</b>		<b>37</b>
A.	Introduction.....	37
B.	Rulemaking.....	38
	1. Rulemaking Under the APA.....	38
	2. Evolution of Rulemaking at FDA.....	39
	a. Early Innovations.....	39
	b. The Statutory Framework.....	40
	c. Judicial Acknowledgment of FDA’s Rulemaking Authority.....	42
	Abbott Laboratories v. Gardner.....	42
	Notes.....	45
	National Association of Pharmaceutical Manufacturers v. Food and Drug Administration.....	46
	Notes.....	51
	3. Rulemaking Procedures.....	52
	a. APA Notice-and-Comment Requirements.....	52
	United States v. Nova Scotia Food Products Corp.....	53
	Notes.....	56
	b. HHS Oversight of FDA Rulemaking.....	56
	c. OMB Oversight of FDA Rulemaking.....	57
	d. Direct Final Rules and Interim Final Rules.....	59
	4. Formal Rulemaking.....	60
	a. When Is a Formal Hearing Required?.....	60
	Dyestuffs and Chemicals, Inc. v. Flemming.....	60
	Notes.....	62
	b. Formal Hearing Procedures.....	63
	c. Alternative Hearings.....	64
	Notice of Proposed Rulemaking: Administrative Practices and Procedures.....	64
C.	Guidance.....	66
	1. Exceptions to APA Rulemaking.....	66
	2. The Rise of Guidance at FDA.....	67
	3. Litigation over Guidance.....	69
	Professionals and Patients for Customized Care v. Shalala.....	69
	Notes.....	75
	4. Good Guidance Practices.....	76
D.	Judicial Review.....	78
	1. Introduction.....	78
	Note.....	79
	2. Standards of Review.....	79

3.	Deference to FDA Decisions .....	80
	Note .....	82
4.	Judicial Review of Agency Inaction .....	82
	a. Enforcement Discretion .....	82
	b. Unreasonable Delay .....	83
	Center for Food Safety v. Hamburg .....	83
	Notes .....	87
5.	Barriers to Judicial Review .....	89
	a. Justiciability .....	89
	Notes .....	89
	b. Primary Jurisdiction .....	90
	Notes .....	91
	c. Exhaustion of Remedies .....	93
E.	Public Information .....	93
	1. Statutory Obligations .....	93
	a. The Freedom of Information Act (FOIA) .....	93
	Notes .....	95
	i. Implementing FOIA: Procedures, Costs, and Backlogs .....	96
	Pharmaceutical Manufacturers Association v. Weinberger .....	96
	Note .....	99
	Judicial Watch, Inc. v. Food & Drug Administration ....	99
	ii. Trade Secrets and Confidential Commercial Information .....	104
	Notes .....	105
	iii. The Scope of Exemption 4 of FOIA .....	108
	Public Citizen Health Research Group v. Food & Drug Administration .....	108
	Note .....	112
	iv. Non-FOIA Disclosure of Clinical Trial Information .....	112
	Notes .....	114
	b. The Shelby Amendment .....	114
	c. The Information Quality Act .....	115
	Notes .....	116
	2. Modern Dissemination of Information .....	117
F.	Advisory Committees .....	118
	1. FDA's Reliance on Advisory Committees .....	119
	Food and Drug Administration Advisory Committees .....	119
	Notes .....	122
	2. Statutory Requirements for Advisory Committees .....	122
	Consumers Union of United States, Inc. v. Department of HEW .....	122
	National Nutritional Foods Ass'n v. Califano .....	126
	Notes .....	129
	Public Citizen v. National Advisory Committee .....	130

	Robert Steinbrook, M.D., <i>Financial Conflicts of Interest and the Food and Drug Administration's Advisory Committees</i> .....	133
	Notes .....	135
<b>Chapter 3. FDA Jurisdiction: A Matter of Definitions .....</b>		<b>139</b>
A.	Introduction.....	139
	Food, Drugs, and Cosmetics .....	139
	United States v. An Article of Drug . . . Bacto-Unidisk.....	140
	Notes .....	142
B.	Food.....	143
	United States v. Tuente Livestock.....	143
	Notes .....	148
	Nutrilab, Inc. v. Schweiker .....	149
	Notes .....	152
C.	Drugs and Devices .....	154
	1. Inclusion in Official Compendia.....	155
	2. Establishing “Intended Use” .....	156
	National Nutritional Foods Ass’n v. Mathews .....	158
	Notes .....	161
	United States v. Travia .....	162
	3. Diagnostic Products .....	164
	United States v. 25 Cases, More or Less, of an Article of Device . . . “Sensor Pad for Breast Self-Examination” .....	164
	Notes .....	166
D.	The Food-Drug Spectrum Adjusted: Health Claims and Dietary Supplements.....	167
	Letter from Felicia B. Satchell, Director, FDA CFSAN Office of Nutritional Products, Labeling and Dietary Supplements, Division of Standards and Labeling Regulations, to Jason S. Crush .....	170
	Notes .....	172
	Warning Letter from Donald D. Ashley, Director, Office of Compliance, CDER- FDA to Edward Chaney, Cannafyl.....	176
	Notes .....	178
E.	Cosmetics.....	179
	Notes .....	180
F.	The Cosmetic-Drug Spectrum .....	181
	1. Cosmetic Claims Versus Drug Claims.....	181
	United States v. An Article . . . Sudden Change .....	181
	Notes .....	184
	Letter From John M. Taylor, FDA Associate Commissioner for Regulatory Affairs, to Various Attorneys Representing the Cosmetic Industry.....	185
	Notes .....	186
	2. The “Active Ingredient” Approach .....	189
	Notes .....	191

G. Exploring the Outer Limits of the Drug and Device Definitions..... 193

1. Cosmetic Devices..... 193

    Letter From Rep. Henry A. Waxman to Tommy Thompson,  
    Secretary of Health and Human Services ..... 194

    Notes ..... 195

2. Common Sense Limits?..... 196

    Notes ..... 198

    Letter From Daniel E. Troy, FDA Chief Counsel, to Jeffrey  
    N. Gibbs ..... 199

    Note ..... 202

    Whether the Food and Drug Administration Has Jurisdiction  
    over Articles Intended for Use in Lawful Executions ..... 203

    Notes ..... 210

3. First Amendment Limits ..... 212

    United States v. 23 . . . Articles..... 212

    United States v. Undetermined Quantities of Article of  
    Device ..... 213

H. Human Biological Products..... 216

    David M. Dudzinski, *Reflections on Historical, Scientific, and Legal  
    Issues Relevant to Designing Approval Pathways for Generic  
    Versions of Recombinant Protein-Based Therapeutics and  
    Monoclonal Antibodies*..... 217

    Notes ..... 219

I. Tobacco Products..... 220

    Deeming Tobacco Products To Be Subject to the Federal Food,  
    Drug, and Cosmetic Act, as Amended by the Family  
    Smoking Prevention and Tobacco Control Act (Final Rule)..... 222

    Notes ..... 225

J. “Label,” “Labeling,” and “Advertising” ..... 225

1. Introduction ..... 225

    Note ..... 226

2. Labeling ..... 226

    Kordel v. United States ..... 226

    Note ..... 228

    United States v. 24 Bottles “Sterling Vinegar & Honey,” etc. .... 228

    Notes ..... 230

3. Advertising ..... 231

4. The Internet..... 232

    Letter From Margaret M. Dotzel, Assoc. Comm. for Policy,  
    FDA, to Daniel J. Popeo and Paul D. Kamenar,  
    Washington Legal Foundation ..... 232

    Notes ..... 233

**Chapter 4. Enforcement and the Geographic Range of FDA**

**Power..... 235**

A. Introduction to Enforcement ..... 235

1. Section 301: Prohibited Acts..... 235

2. Tools of Enforcement ..... 236

    Note ..... 237

3.	FDA Enforcement Statistics.....	237
	Notes .....	238
4.	FDA Enforcement Policy .....	239
	Remarks by Margaret A. Hamburg, Commissioner of Food and Drugs, “Effective Enforcement and Benefits to Public Health” .....	239
	Notes .....	240
B.	Enforcement Jurisdiction .....	241
1.	“Introduction into Interstate Commerce” .....	242
	United States v. Sanders .....	243
	Notes .....	244
2.	“Held for Sale After Shipment in Interstate Commerce” .....	245
	United States v. Kaplan .....	246
	Notes .....	250
3.	Components Shipped in Interstate Commerce .....	253
	Baker v. United States .....	254
	Notes .....	256
4.	Devices and Tobacco Products.....	257
5.	Biologics.....	258
	United States v. Calise .....	258
	Notes .....	259
C.	Enforcement Consistency, Selectivity, and Discretion.....	261
1.	Administrative Consistency and Selective Enforcement .....	261
	United States v. Undetermined Quantities of an Article of Drug Labeled as Exachol.....	261
	Notes .....	263
2.	Enforcement Discretion .....	265
	Heckler v. Chaney .....	265
	Notes .....	269
D.	Factory Inspection .....	272
1.	Introduction.....	272
	FDA Investigations Operations Manual, Chapter 5 (“Establishments Inspection”) .....	273
	Notes .....	275
2.	Constitutional Limitations .....	276
	United States v. Jamieson-McKames Pharmaceuticals, Inc.....	276
	Notes .....	280
3.	Scope of Inspections .....	281
a.	Records.....	281
	Notes .....	282
b.	Samples.....	285
	Triangle Candy Co. v. United States .....	285
	Notes .....	286
c.	Photographs.....	287
	Frederick H. Branding & James M. Ellis, <i>Underdeveloped: FDA’s Authority to Take Photographs During an FDA Establishment Inspection Under Section 704</i> .....	287
	Notes .....	289

4.	The USDA Inspection Regime .....	290
E.	Seizure .....	292
1.	Introduction .....	292
	Peter Barton Hutt, <i>Philosophy of Regulation Under the</i> <i>Federal Food, Drug and Cosmetic Act</i> .....	292
	Note .....	293
2.	The Seizure Process .....	293
	United States of America v. Argent Chemical Laboratories, Inc.....	293
	Notes .....	297
3.	Pre-Conviction Release .....	298
	United States v. Undetermined Quantities of Drugs .....	298
	Notes .....	301
4.	Multiple Seizures .....	301
	Ewing v. Mytinger & Casselberry, Inc. ....	302
	Notes .....	304
5.	Proof Required for Conviction.....	305
	United States v. 43 1/2 Gross Rubber Prophylactics Labeled in Part “Xcello’s Prophylactics” .....	305
	Notes .....	306
6.	Final Conviction Decrees and Salvaging .....	307
	United States v. 1,638 Cases of Adulterated Alcoholic Beverages.....	307
	Notes .....	310
7.	Administrative Detention.....	310
F.	Injunctions.....	311
1.	Introduction .....	311
	Notes .....	312
2.	Preliminary Injunctions.....	313
	United States v. Nutri-cology, Inc.....	313
3.	Permanent Injunctions .....	315
	United States v. Laerdal Manufacturing Corp. ....	315
	Notes .....	318
4.	Consent Decrees, Restitution, and Disgorgement .....	319
	Department of Justice Press Release .....	319
	William W. Vodra & Arthur N. Levine, <i>Anchors Away:</i> <i>The Food and Drug Administration’s Use of</i> <i>Disgorgement Abandons Legal Moorings</i> .....	321
	Notes .....	324
G.	Recalls.....	325
1.	Voluntary Recalls .....	325
	Enforcement Policy, Practices and Procedures: Recall Policy and Procedures .....	326
	Notes .....	329
2.	Mandatory Recalls .....	330
	Notes .....	332
H.	Criminal Liability .....	334
1.	Introduction .....	334
	Sam D. Fine, <i>The Philosophy of Enforcement</i> .....	334

	Notes .....	335
2.	Standard of Liability.....	336
	a. Criminal Liability of Responsible Corporate Officials.....	336
	United States v. Park.....	338
	United States v. DeCoster .....	344
	Notes .....	347
	b. The Defense of Impossibility .....	350
3.	The Guaranty Clause.....	351
	Notes .....	351
I.	Debarment and Exclusion.....	352
	1. Debarment.....	352
	Bae v. Shalala.....	353
	Notes .....	357
	2. Exclusion .....	357
	Friedman v. Sebelius .....	357
	Notes .....	362
J.	Civil Money Penalties.....	363
	Notes.....	364
K.	Informal Compliance Correspondence.....	365
	FDA Regulatory Procedures Manual, Chapter 4 (“Advisory Actions”).....	365
	Notes.....	368
L.	Publicity.....	370
	Hoxsey Cancer Clinic v. Folsom.....	370
	Notes.....	371
M.	Regulation of Foreign Commerce.....	373
	1. Introduction.....	373
	a. International Offices and Arrangements.....	373
	b. International Trade Agreements .....	374
	2. Importation into the United States .....	376
	a. FDA’s General Authority over Importation.....	376
	Sugarman v. Forbragd .....	376
	Notes .....	377
	Cook v. FDA.....	378
	Notes .....	384
	b. Reconditioning, Destroying, or Reexporting Goods Refused Admission .....	386
	Carl Borchsenius Co. v. Gardner .....	387
	c. Refusal of Admission Compared to Seizure.....	389
	United States v. Food, 2,998 Cases.....	389
	Notes .....	393
	3. Importation of Food .....	394
	Notes .....	396
	4. Importation of Prescription Drugs.....	397
	a. Commercial Importation.....	397
	Warning Letter From David J. Horowitz, Dir., CDER Office of Compliance, to Harry Lee Jones, Store Manager, Rx Depot, Inc. ....	397



	United States of America v. Rx Depot, Inc. ....	400
	Notes .....	403
b.	Importation for Personal Use .....	404
c.	Importation Pursuant to Waiver .....	404
	State of Vermont v. Leavitt .....	404
	Notes .....	406
5.	Exportation Pursuant to Section 801(e)(1) .....	408
a.	General.....	408
	United States v. Kanasco, Ltd. ....	409
	Notes .....	411
b.	Exportation of Unapproved New Drugs and Unlicensed Biologics .....	412
	United States v. An Article of Drug . . . Ethionamide-INH .....	412
	Notes .....	413
c.	Exportation of Unapproved New Animal Drugs .....	414
d.	Exportation of Unapproved Devices.....	415
6.	Exportation of Unapproved Medical Products Pursuant to Section 802.....	416
	Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 .....	416
	Notes .....	421
7.	Import for Export .....	422
	FDA Regulatory Procedures Manual, Chapter 9 (“Import Operation and Actions”).....	422
N.	The Relationship Between FDA and the States .....	424
1.	The Elusive Goal of Uniformity of State Laws.....	424
	Melvin Hinich & Richard Staelin, <i>Regulation of the U.S. Food Industry</i> .....	426
2.	Introduction to Federal Preemption .....	428
a.	Basics of the Doctrine .....	428
b.	Historical Background .....	429
3.	Field Preemption.....	431
	Hillsborough County v. Automated Medical Laboratories, Inc.....	431
	Notes .....	434
4.	Conflict Preemption .....	436
a.	Impossibility Preemption.....	436
	Grocery Manufacturers of America v. Gerace .....	436
	Notes .....	438
b.	Obstacle Preemption .....	439
	Florida Lime & Avocado Growers, Inc. v. Paul .....	439
	Jones v. Rath Packing Co. ....	442
	Notes .....	446
5.	Express Preemption .....	448
a.	Devices .....	449
	Notes .....	450
b.	Food Labeling .....	451
	Notes .....	453

c.	Nonprescription Drugs and Cosmetics .....	453
	Note .....	454
d.	Tobacco Products .....	454
<b>Chapter 5. Food .....</b>		<b>457</b>
A.	Subcategories of Food .....	457
1.	Food Regulated Primarily by Agencies Other than FDA .....	457
a.	Meat, Poultry, and Eggs .....	458
b.	Alcoholic Beverages.....	460
c.	Water and Ice .....	461
2.	Dietary Supplements .....	461
	Warning Letter From Michael W. Roosevelt, Acting Director, CFSAN Office of Compliance, to Terry Harris, HBB, LLC dba Baked World.....	462
	Notes .....	463
3.	Other FDA-Regulated Foods with Special Requirements .....	466
a.	Infant Foods.....	466
b.	Medical Foods .....	466
c.	Hypoallergenic Foods .....	467
d.	Diet Foods .....	468
B.	Historical Overview of FDA Regulation of Food Identity, Quality, and Labeling.....	468
C.	What's in a Name? Regulation of Food Identity and Quality .....	475
1.	Food Standards of Identity.....	476
a.	Strong Standards of Identity: The Filled Milk Act .....	477
	United States v. Carolene Products Co.....	477
	Notes .....	479
	Milnot Co. v. Richardson .....	480
	Notes .....	482
b.	The Formation and Zenith of the FD&C Act Food Standards Regime .....	482
	Federal Security Administrator v. Quaker Oats Co. ....	484
	Notes .....	487
	Richard A. Merrill & Earl M. Collier, <i>"Like Mother Used         to Make": An Analysis of FDA Food Standards         of Identity</i> .....	488
	Notes .....	489
	62 Cases of Jam v. U.S.....	492
	Notes .....	493
c.	The Declining Significance of Food Standards.....	494
i.	"Safe and Suitable Ingredients" .....	494
ii.	Redefining "Imitation" .....	495
iii.	Rise and Fall of "Alternative"/"Substitute" Nomenclature .....	495
iv.	New Understanding of "Purports to Be" .....	496
v.	The Abandonment of Food Standards as a Primary Vehicle for Fortification and Vitamin/Mineral Supplement Policy .....	498

2.	The Modern Food-Naming Regime .....	500
a.	The Persistence of Food Standards .....	500
	Food Standards; General Principles and Food Standards Modernization: Proposed Rule .....	501
	Notes .....	502
	Notes .....	504
	Gitson v. Trader Joe's Co. ....	506
	Notes .....	508
b.	Regulation of Common or Usual Food Names for Nonstandardized Foods .....	509
	Common or Usual Names for Nonstandardized Foods .....	510
	21 C.F.R. Part 102—Common or Usual Name for Nonstandardized Foods .....	511
	American Frozen Food Institute v. Mathews .....	513
	Notes .....	515
	POM Wonderful LLC v. Coca-Cola Co. ....	517
	Notes .....	521
c.	Limited Use of “Imitation” .....	521
	Imitation Foods, Application of Term “Imitation”: Proposed Rulemaking .....	522
	Notes .....	523
	Federation of Homemakers v. Schmidt .....	524
	Notes .....	525
d.	The Use of Nutrient Descriptors (“Nutrient Content Claims”) in Food Names .....	525
	21 C.F.R. § 130.10. Requirements for Foods Named by Use of a Nutrient Content Claim and a Standardized Term .....	526
	Notes .....	528
3.	Economic Adulteration .....	529
	United States v. 88 Cases . . . Bireley's Orange Beverage .....	529
	Notes .....	531
D.	Regulation of Food Labeling .....	532
1.	“False or Misleading in Any Particular” .....	532
	United States v. Ninety-Five Barrels of . . . Apple Cider Vinegar .....	533
	United States v. 432 Cartons . . . Candy Lollipops .....	535
	Notes .....	536
	United States v. Farinella .....	537
	Notes .....	540
2.	Mandatory Information and Disclosures .....	543
a.	Prominence and Conspicuousness .....	544
	21 C.F.R. Part 101—Food Labeling .....	544
b.	Net Quantity of Contents .....	545
	Note .....	546
c.	Ingredient Labeling .....	546
	Notes .....	547

	FDA Response to Petition From Corn Refiners Association to Authorize “Corn Sugar” as an Alternate Common or Usual Name for High Fructose Corn Syrup (HFCS) .....	550
	Notes .....	552
d.	Allergen Disclosure .....	553
e.	Mandatory Warning Statements .....	555
	Food, Drug and Cosmetic Products, Warning Statements (Final Rule) .....	555
	Notes .....	556
f.	Nutrition Facts .....	559
	Notes .....	560
g.	Mandatory Country of Origin Labeling .....	566
3.	Voluntary Claims .....	567
a.	Introduction .....	567
	Lewis A. Grossman, <i>Food, Drugs, and Droids: A Historical Consideration of Definitions and Categories in American Food and Drug Law</i> .....	567
b.	Categories of Claims Related to Health .....	571
c.	Nutrient Descriptors (“Nutrient Content Claims”) .....	572
	21 C.F.R. § 101.62. Nutrient Content Claims for Fat, Fatty Acid, and Cholesterol .....	573
	Notes .....	574
d.	“Healthy” Claims .....	576
	Guidance: Use of the Term “Healthy” in the Labeling of Human Food Products .....	577
	Notes .....	579
e.	NLEA Disease Prevention Claims (“Unqualified Health Claims”) .....	579
	Food Labeling; General Requirements for Health Claims for Food (Final Rule) .....	582
	Notes .....	584
	Warning Letter from W. Charles Becoat, Director, FDA Minneapolis District, to Ken Powell, CEO, General Mills .....	588
	Notes .....	590
f.	Structure/Function Claims .....	590
	Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body (Proposed Rule) .....	592
	21 CFR § 101.93. Certain Types of Statements for Dietary Supplements .....	595
	Notes .....	596
	Dachauer v. NBTY, Inc. .....	600
g.	Other Common Voluntary Food Claims .....	604
i.	“Natural” .....	604
	Scholder v. Riviana Foods .....	604
	Notes .....	607

ii.	“Fresh” .....	608
iii.	“Organic” .....	609
	Notes.....	610
h.	FTC Regulation of Food Advertising.....	612
	Note .....	614
4.	The First Amendment and Food Labeling .....	614
a.	Introduction .....	614
b.	Disease Prevention Claims Based on Credible Scientific Evidence (“Qualified Health Claims”).....	615
	Pearson v. Shalala.....	616
	Whitaker v. Thompson.....	620
	Fleminger v. HHS .....	624
	Notes .....	627
c.	The First Amendment and Mandatory Information in Food Labeling .....	628
	American Meat Institute v. USDA.....	629
	Note .....	632
5.	Labeling of Genetically Modified Foods.....	632
	Food and Drug Administration, Statement of Policy: Foods Derived From New Plant Varieties.....	633
	Alliance for Bio-Integrity v. Shalala .....	634
	Agricultural Marketing Service, National Bioengineered Food Disclosure Standard (Final Rule).....	637
	Note.....	640
	International Dairy Foods Association v. Amestoy .....	640
	Notes .....	644
E.	Food Sanitation and Aesthetic Adulteration .....	646
1.	“Filthy, Putrid, or Decomposed Substance”.....	647
	United States v. 1,500 Cases More or Less, Tomato Paste .....	647
	Notes .....	650
	Natural or Unavoidable Defects in Food for Human Use That Present No Health Hazard: Public Availability of Information (Proposed Rule) .....	651
	Notes .....	652
	Melvin J. Hinich & Richard Staelin, <i>Regulation of the U.S.</i> <i>Food Industry</i> .....	654
	Notes .....	655
	United States v. 1,200 Cans . . . Pasteurized Whole Eggs, etc. ....	656
	Note.....	659
2.	“Prepared Under Insanitary Conditions . . . Whereby It May Have Become Contaminated with Filth” .....	659
	Berger v. United States .....	660
	Notes .....	662
3.	“Otherwise Unfit for Food” .....	663
	United States v. 298 Cases . . . Ski Slide Brand Asparagus .....	663
	Notes .....	664

F.	The Presence of Poisonous or Deleterious Substances .....	666
1.	Introduction to FDA’s Regulation of the Safety of Food Constituents .....	666
2.	Nonadded Substances and the “Ordinarily Injurious” Standard .....	670
	United States v. 1232 Cases American Beauty Brand Oysters .....	670
	Notes .....	672
3.	Added Substances and the “May Render Injurious” Standard ...	673
	United States v. Lexington Mill & Elevator Co. ....	674
	Notes .....	676
	United States v. Anderson Seafoods, Inc. ....	677
	Notes .....	680
	Continental Seafoods v. Schweiker .....	681
	Notes .....	684
4.	Tolerances and Action Levels for Unavoidable Poisonous or Deleterious Substances .....	687
a.	Section 406 Tolerances .....	687
b.	Action Levels: Legal Basis and Procedure .....	689
	Poisonous or Deleterious Substances in Food: Notice of Proposed Rulemaking .....	689
	Note .....	691
	Young v. Community Nutrition Institute .....	692
	Note .....	695
c.	Action Levels: The Example of Mercury .....	696
	Action Level for Mercury in Fish and Shellfish: Notice of Proposed Rulemaking .....	696
	Notes .....	697
d.	The Question of Blending .....	699
	Note .....	699
G.	Regulation of Food Production and the Problem of Pathogenic Microorganisms .....	700
1.	Introduction .....	700
	Enhancing Food Safety: The Role of the Food and Drug Administration .....	702
	Note .....	704
	Background on the FDA Food Safety Modernization Act .....	704
	Notes .....	707
2.	Good Manufacturing Process (GMP) Regulations .....	710
	United States v. Nova Scotia Food Products Corp. ....	712
	Notes .....	714
3.	Mandatory Pasteurization .....	716
	Requirements Affecting Raw Milk for Human Consumption in Interstate Commerce: Final Rule .....	716
	Notes .....	721
4.	Emergency Permit Control .....	722
	Notes .....	723

5.	Hazard Analysis and Critical Control Points (HACCP) .....	724
	Food and Drug Administration Development of Hazard Analysis Critical Control Points for the Food Industry: Advanced Notice of Proposed Rulemaking .....	724
	Notes .....	730
H.	Intentional Functional Ingredients .....	732
1.	Introduction .....	732
	Investigation of the Use of Chemicals in Foods and Cosmetics .....	732
	Food Additives Amendment of 1958 .....	733
	Note .....	735
2.	Food Additive Approval .....	735
	21 C.F.R. § 172.867. Olestra .....	737
	Marion Nestle, <i>The Selling of Olestra</i> .....	738
	Henry I. Miller, <i>Who Is Trying to Kill Olestra? and Why?</i> .....	741
	Notes .....	742
	Notes: Specific Additives .....	745
3.	The Meaning of “Food Additive” .....	747
	United States v. An Article of Food . . . FoodScience Labs .....	749
	United States v. Two Plastic Drums . . . Black Currant Oil .....	751
	Notes .....	752
	National Nutritional Foods Ass’n v. Kennedy .....	753
	Notes .....	755
4.	The Deterioration of the Food Additive Approval Process .....	755
	Peter Barton Hutt, <i>Regulation of Food Additives in the United States</i> .....	755
	Note .....	757
5.	Procedures for Establishing Generally Recognized as Safe (GRAS) Status .....	757
a.	FDA GRAS Lists .....	757
b.	Voluntary GRAS Notice .....	758
c.	Self-Determination (Independent Conclusion) of GRAS Status .....	759
	Ctr. for Food Safety v. Becerra .....	761
	Notes .....	765
6.	Substantive Criteria for GRAS Status .....	766
	Substances Generally Recognized as Safe .....	766
	Notes .....	769
	United States v. An Article of Food . . . Coco Rico, Inc. .....	771
	Notes .....	772
	Fmali Herb, Inc. v. Heckler .....	773
	Notes .....	775
	Agency Response Letter GRAS Notice No. 000737, From Dennis M. Keefe, Director, CFSAN Office of Food Additive Safety to Gary Yingling .....	775
	Note .....	777

	Warning Letter from Joann M. Givens, Acting Director, CFSAN Office of Compliance, to Jaisen Freeman et al., Phusion Projects, LLC .....	777
	Note .....	779
7.	Loss of GRAS Status .....	780
	Final Determination Regarding Partially Hydrogenated Oils .....	780
	Notes .....	784
8.	The GRAS Presumption for Genetically Modified Ingredients .....	784
	FDA Statement of Policy: Foods Derived From New Plant Varieties .....	785
	Notes .....	789
	Alliance for Bio-Integrity v. Shalala .....	789
	Notes .....	790
9.	Prior Sanctioned Substances .....	792
	Proposal Regarding Regulation of Prior-Sanctioned Food Ingredients .....	792
	Notes .....	793
10.	Food Packaging and Processing Substances .....	795
	Natick Paperboard Corp. v. Weinberger .....	797
	Monsanto Co. v. Kennedy .....	799
	Notes .....	803
11.	Color Additive Regulation .....	806
	a. Historical Background .....	806
	b. The Color Additives Amendment .....	807
	Notes .....	808
	Kalsec, Inc., Citizen Petition Requesting FDA to Enforce Ban on Carbon Monoxide Gas in Fresh Meat Packaging .....	810
	Notes .....	814
	FD&C Yellow No. 5: Labeling in Food and Drugs for Human Use .....	815
	Notes .....	816
12.	Dietary Ingredients in Dietary Supplements .....	817
	Notes .....	818
	Nutraceutical Corporation v. Von Eschenbach .....	820
	Notes .....	823
13.	Animal Drug Residues .....	824
14.	Pesticide Residues .....	825
	Notes .....	826
	Notes .....	828
<b>Chapter 6. Human Drugs .....</b>		<b>831</b>
A.	Historical Background .....	831
	1. Drug Regulation Before the 1938 FD&C Act .....	831
	Note .....	832



2.	Drug Regulation Under the 1938 FD&C Act and 1962 Amendments.....	832
	Note.....	834
3.	Regulation of Drug Efficacy: History and Policy.....	834
	American School of Magnetic Healing v. McAnnulty .....	835
	Research Laboratories, Inc. v. United States.....	839
	Rutherford v. United States .....	842
	Notes .....	844
	Abigail Alliance v. Von Eschenbach.....	846
	Note.....	853
B.	The Concept of a “New Drug”.....	853
1.	GRAS/GRAE Status.....	854
	Weinberger v. Hynson, Westcott & Dunning, Inc. ....	854
	Notes .....	858
2.	The “Grandfather” Clauses .....	859
3.	Jurisdiction to Determine New Drug Status.....	860
	Weinberger v. Bentex Pharmaceuticals, Inc. ....	860
	Note.....	862
C.	Drug Development and FDA Approval of New Drugs.....	863
	Richard Merrill, <i>The Architecture of Government Regulation of Medical Products</i> .....	863
	Notes .....	865
1.	Drug Discovery and Nonclinical Testing .....	865
	Amy M. Avila et al., <i>An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)</i> .....	866
	Notes .....	868
2.	Clinical Testing .....	870
	Notes .....	871
a.	The Investigational New Drug Application (IND) .....	871
i.	The IND Requirement.....	871
	Notes.....	873
ii.	Human Subject Protection .....	874
	Note .....	875
	(a) Informed Consent .....	875
	21 C.F.R. § 50.25. Elements of Informed Consent.....	876
	Notes.....	877
	(b) Institutional Review Board Review.....	879
	Notes.....	880
iii.	Clinical Testing Outside the United States.....	881
	Note .....	882
b.	The Clinical Program .....	883
i.	The Testing Sequence .....	883
	Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies.....	884
	Notes.....	886
ii.	Protocol Amendments .....	887

iii.	Clinical Trial Design .....	887
(a)	The “Adequate and Well-Controlled” Investigation .....	887
	21 C.F.R. § 314.126. Adequate and Well- Controlled Studies .....	887
	Notes.....	889
(b)	Clinical Endpoints and Surrogate Endpoints.....	891
	James Bilstad, M.D., “Surrogate Endpoints” .....	892
	Notes.....	894
iv.	Subpopulations .....	895
(a)	Children.....	896
	Note .....	899
(b)	The Elderly.....	899
(c)	Subjects with Childbearing Potential .....	900
(d)	Racial and Ethnic Diversity.....	901
	Notes.....	901
v.	Meetings with FDA and Special Protocol Assessments.....	902
(a)	Meetings.....	902
	Guidance for Industry and Review Staff: Best Practices for Communication Between IND Sponsors and FDA During Drug Development.....	902
	Draft Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products .....	903
	Notes.....	905
(b)	Special Protocol Assessment.....	906
	Guidance for Industry: Special Protocol Assessment.....	907
	Note .....	909
vi.	Data Monitoring Committees .....	909
	Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees .....	910
	Notes.....	911
c.	FDA Oversight.....	911
i.	Reporting and Recordkeeping.....	911
ii.	The Clinical Hold.....	911
	Notes.....	912
iii.	Investigator Non-Compliance and Fraud .....	913
	Notes.....	914
iv.	Inspections .....	914
v.	Good Manufacturing Practice.....	915
	Note .....	916
vi.	Clinical Trial Registration and Results Reporting .....	916
3.	The New Drug Application .....	918
a.	Preparation and Submission of the NDA .....	918

i.	Content of the NDA.....	918
	New Drug Application (NDA).....	918
	Notes.....	920
ii.	User Fees .....	922
	Congressional Research Service, FDA Human Medical Product User Fee Programs.....	923
	Notes.....	926
iii.	The Filing Decision.....	926
	Notes.....	926
b.	FDA's Review Process .....	927
i.	Deadline for Decision .....	927
ii.	Agency Review Process .....	928
	Notes.....	930
iii.	Advisory Committee Review.....	930
	Peter Barton Hutt, <i>The Regulation of Drug Products         by the United States Food and Drug         Administration</i> .....	931
	Note .....	931
c.	The Approval Decision .....	932
i.	The Safety Standard .....	932
	Testimony of FDA Commissioner George Larrick .....	932
	Michael A. Friedman et al., <i>The safety of newly         approved medicines: do recent market         removals mean there is a problem?</i> .....	934
	Managing the Risks from Medical Product Use: Report to the FDA Commissioner from the Task Force on Risk Management .....	934
	Scott Gottlieb, M.D., <i>The Price of Too Much         Caution</i> .....	935
	Notes.....	936
ii.	The Effectiveness Standard .....	938
	Notes.....	941
iii.	Balancing Benefit and Risk .....	944
	Testimony of FDA Commissioner George Larrick .....	944
	Kathleen Miller, PhD & Janet Woodcock, MD, <i>Value Assessment in the Regulatory Context</i> .....	945
	Notes.....	947
iv.	Labeling Review .....	949
	House of Representatives.....	949
v.	Final Approval or Denial .....	951
	Ubiotica Corp. v. FDA .....	952
	Notes.....	953
4.	The Impact of the 1962 Amendments.....	956
	Richard Merrill, <i>The Architecture of Government Regulation of         Medical Products</i> .....	956
a.	Impact on Innovation .....	957
	Statement of Sam Peltzman .....	957
	Notes .....	960

b.	The Risk, Duration, and Cost of New Drug Research and Development.....	960
i.	The Risk.....	960
ii.	The Duration.....	961
iii.	The Cost.....	963
D.	Variations on, and Exceptions to, the Standard Drug Development and Approval Process.....	964
1.	Expediting Development and Approval of Drugs for Serious Conditions.....	964
a.	Fast Track.....	965
i.	The FDA Regulations (“Subpart E”).....	965
Investigational New Drug, Antibiotic, and Biological Drug Product Regulations: Procedures for Drugs Intended to Treat Life-Threatening and Severely Debilitating Illnesses.....	965	
ii.	The Statute.....	966
Notes.....	967	
b.	Breakthrough Therapy.....	967
Notes.....	968	
c.	Accelerated Approval.....	968
Note.....	969	
i.	Approval Based on a Surrogate Endpoint.....	969
Findings; Sense of Congress.....	970	
Julia A. Beaver, MD, et al., <i>A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review</i> .....	972	
Notes.....	974	
ii.	Approval Conditioned on Restricted Distribution.....	975
d.	Priority Review.....	976
CDER Manual of Policies and Procedures 6020.3 Rev.2 Review Designation Policy: Priority (P) and Standard (S).....	976	
Notes.....	978	
e.	Limited Population Pathway for Antibacterial and Antifungal Drugs.....	979
2.	Use of Investigational New Drugs for Therapy.....	980
a.	Introduction.....	980
Notes.....	982	
b.	Types of Expanded Access Programs.....	986
i.	Individual Patient IND or Protocol.....	986
Notes.....	986	
ii.	Emergency Use IND or Protocol.....	987
iii.	Intermediate-Size Patient Population IND or Protocol.....	987
Note.....	988	
iv.	Treatment IND or Protocol.....	988
Notes.....	989	
v.	Promoting and Charging for Expanded Access.....	990

---

c.	The Right-to-Try Laws.....	991
	Note .....	993
3.	Emergency Use Authorization .....	993
	Notes .....	994
4.	Unapproved Prescription Drugs.....	995
a.	Pre-1962 DESI Drugs.....	995
i.	Marketing of Drugs Under the 1938 FD&C Act.....	995
	Note .....	996
ii.	The 1962 Drug Amendments and the NAS Review .....	996
iii.	The Commencement of NDA-Withdrawal Proceedings .....	998
iv.	Manufacturers Challenge DESI in Court .....	999
v.	Finding a Path Forward for “Me-Too” Drugs .....	1000
vi.	The Elusive Goal of DESI Completion .....	1003
	Notes.....	1004
b.	Non-DESI Unapproved Prescription Drugs .....	1004
	Notes .....	1008
5.	Traditional Exceptions to the NDA Requirement.....	1010
a.	Homeopathic Drugs.....	1010
	Note .....	1012
b.	Traditional Chinese Medicine .....	1012
6.	The Practice of Pharmacy.....	1012
	FDA’s Oversight of NECC and Ameridose: A History of Missed Opportunities .....	1013
	Guidance: Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act.....	1016
	Notes .....	1019
7.	Other Special Situations.....	1020
a.	Radiopharmaceutical Drugs .....	1020
	Guidance: Compounding and Repackaging of Radiopharmaceuticals by Outsourcing Facilities.....	1020
	Syncor International Corporation v. Shalala .....	1023
	Notes .....	1026
b.	Botanical Drugs.....	1027
c.	Medical Gas .....	1027
d.	Insulin and Antibiotic Drugs (Historically).....	1027
	Note .....	1028
e.	Importation of Unapproved New Drugs .....	1028
	Coverage of Personal Importations .....	1030
	Notes .....	1032
8.	Modernizing the Drug Development and Approval Process .....	1034
	Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science .....	1034
	Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development.....	1037
	Notes .....	1038

E.	Prescription Status and Other Restrictions on Distribution .....	1039
1.	Limitation to Prescription Sale .....	1039
a.	Legal Basis.....	1039
	Peter Temin, <i>The Origin of Compulsory Drug</i>	
	<i>Prescriptions</i> .....	1040
	United States v. El-O-Pathic Pharmacy .....	1041
	Notes .....	1044
b.	Authority to Prescribe and the Requirement of a Valid	
	Prescription .....	1045
	Notes .....	1047
2.	Scheduled Prescription Drugs.....	1047
a.	Cannabis and Its Derivatives.....	1048
	Note .....	1050
b.	The Opioid Crisis.....	1051
	Notes .....	1052
3.	The (Non)Regulation of the Practice of Medicine .....	1053
a.	Development of FDA’s Practice of Medicine Policy .....	1054
	New Drugs Used for Nonapproved Purposes	
	(Methotrexate for Psoriasis) .....	1055
	Legal Status of Approved Labeling for Prescription	
	Drugs; Prescribing for Uses Unapproved by the	
	Food and Drug Administration: Notice of	
	Proposed Rule Making .....	1056
	Notes .....	1058
	United States v. Evers .....	1062
	Note .....	1066
4.	Use and Distribution Restrictions Imposed by FDA .....	1066
a.	Before 2007 .....	1066
	American Pharmaceutical Association v. Weinberger.....	1066
	Notes .....	1069
	Speech by Scott Gottlieb, M.D., Before the American	
	Medical Association.....	1071
b.	Risk Evaluation and Mitigation Strategies (REMS) .....	1072
	Risk Evaluation and Mitigation Strategy (REMS)	
	Document .....	1074
	Notes .....	1075
F.	Physician Labeling and Patient Labeling for Prescription Drugs....	1076
1.	Physician Labeling (Prescribing Information) .....	1076
a.	Purpose and Content.....	1076
	Notes .....	1079
b.	Safety-Related Language.....	1081
	Bradley v. Weinberger .....	1083
	Notes .....	1085
	Labeling: Failure to Reveal Material Facts.....	1086
	Notes .....	1087
c.	Drug Names.....	1089
i.	The Nonproprietary Name.....	1089
	Administered Prices—Drugs .....	1090
	Notes.....	1091

ii.	Proprietary Names .....	1092
	Notes.....	1092
2.	Patient Labeling for Prescription Drugs .....	1093
a.	Mandatory Patient Labeling: Patient Package Inserts (PPIs).....	1094
	Statement of Policy Concerning Oral Contraceptive Labeling Directed to Users .....	1094
	Note .....	1097
	Pharmaceutical Manufacturers Association v. FDA.....	1097
	Notes .....	1100
b.	The Rise of Voluntary Patient Labeling .....	1100
	Prescription Drug Products: Patient Labeling Requirements.....	1101
	Prescription Drug Products: Revocation of Patient Package Insert Requirements.....	1102
	Notes .....	1104
c.	Modern Mandatory Patient Labeling: Medication Guides .....	1104
	Note .....	1105
G.	After NDA Approval .....	1106
1.	Establishment Registration and Drug Product Listing .....	1106
	Notes .....	1106
2.	Adverse Event Reporting and Other Postmarket Monitoring .....	1107
	Notes .....	1108
3.	Supplemental NDAs (sNDAs) .....	1109
4.	Postmarket Testing.....	1110
	Guidance for Industry: Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act .....	1112
	Note.....	1113
5.	Safety-Related Labeling Changes.....	1113
	Notes .....	1114
6.	Good Manufacturing Practices (GMPs) .....	1115
a.	Background.....	1115
	United States v. An Article of Drug . . . White Quadrisect.....	1115
	Human and Veterinary Drugs: Current Good Manufacturing Practice in Manufacture, Processing, Packing, or Holding .....	1117
	Notes .....	1119
b.	Enforcement.....	1120
	United States v. Barr Laboratories, Inc. ....	1121
c.	Modernization.....	1123
	Pharmaceutical CGMPs for the 21st Century: A Risk- Based Approach .....	1123
	Notes .....	1125

---

7.	Voluntary Withdrawal from the Market .....	1126
	Statement of Sandra L. Kweder, Deputy Director, CDER	
	Office of New Drugs .....	1127
	Bernadine Healy, M.D., <i>What Is a ‘Safe’ Drug?</i> .....	1128
	Notes .....	1129
8.	Withdrawal of NDA Approval .....	1130
	Weinberger v. Hynson, Westcott & Dunning, Inc. ....	1130
	Notes .....	1133
9.	Summary Ban Based on an “Imminent Hazard” .....	1134
	Forsham v. Califano .....	1135
	Notes .....	1139
H.	Communicating About Prescription Drugs .....	1141
1.	Introduction .....	1141
2.	Advertising and Promotion to Healthcare Professionals .....	1142
a.	Advertising to Healthcare Professionals .....	1142
	21 C.F.R. § 202.1. Prescription-Drug Advertisements .....	1142
	Notes .....	1145
b.	Labeling .....	1147
	Note .....	1148
3.	Direct-to-Consumer Promotion .....	1149
a.	Print Advertising to Consumers .....	1149
	Direct-to-Consumer Advertising of Prescription Drugs;	
	Withdrawal of Moratorium .....	1149
	Notes .....	1150
b.	Broadcast Advertising .....	1150
	Draft Guidance for Industry: Consumer-Directed	
	Broadcast Advertisements .....	1151
	Guidance for Industry: Consumer-Directed Broadcast	
	Advertisements .....	1152
	Notes .....	1153
	Warning Letter From Thomas Abrams, Dir., DDMAC to	
	Reinhard Franzen, Pres. & CEO, Bayer HealthCare	
	Pharmaceuticals, Inc. ....	1154
c.	General Issues Relating to Promotion to Consumers .....	1158
	Keeping Watch Over Direct-to-Consumer Ads .....	1158
	Notes .....	1159
4.	Communications About Off-Label Uses .....	1161
a.	Off-Label Promotion in Labeling .....	1163
b.	Off-Label Promotion in Advertising .....	1164
c.	Off-Label Promotion in Oral Statements and FDA’s	
	“Squeeze Play” .....	1164
i.	The “Squeeze Play” in the OTC Context .....	1165
	U.S. v. Articles of Drug . . . Foods Plus .....	1165
	Notes .....	1168
ii.	The “Squeeze Play” in the Prescription Context .....	1169
	Memorandum of Law in Support of Motion for	
	Preliminary Injunction .....	1170



d.	The Government’s Use of Other Statutes to Enforce the Prohibition Against Off-Label Promotion .....	1171
	United States ex rel. Franklin v. Parke-Davis .....	1172
	Notes .....	1175
e.	Permitted Communication About Unapproved Uses .....	1176
i.	Scientific Exchange and Disclosures Required by Law .....	1177
ii.	Responses to Unsolicited Requests for Information .....	1177
	Draft Guidance for Industry: Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices .....	1178
	Note .....	1180
iii.	Distribution of Scientific Literature About Unapproved Uses .....	1181
	Washington Legal Foundation v. Henney .....	1182
	Note .....	1186
	Revised Draft Guidance for Industry: Distributing Scientific and Medical Publications on Unapproved New Uses—Recommended Practice .....	1188
	Note .....	1192
iv.	The Full Extent of First Amendment Protection .....	1192
	United States v. Caronia .....	1192
	Amarin Pharma, Inc. v. U.S. Food and Drug Administration .....	1200
	Notes .....	1203
5.	Preapproval Promotion .....	1206
6.	Other Regulators .....	1207
	FDA and SEC Work to Enhance Public’s Protection From False and Misleading Statements .....	1207
7.	Relationships with Healthcare Professionals .....	1207
	Notes .....	1209
I.	Over-the-Counter Drugs .....	1210
1.	Distinguishing Between Prescription and OTC Drugs .....	1210
	United States v. Article of Drug . . . “Decholin” .....	1210
	Note .....	1213
	Peter Barton Hutt, <i>A Legal Framework for Future Decisions on Transferring Drugs From Prescription to Nonprescription Status</i> .....	1214
	Notes .....	1216
2.	Switches from Prescription to Nonprescription Status .....	1217
	Notes .....	1220
	Tummino v. Hamburg .....	1222
	Notes .....	1229
3.	The OTC Drug Review .....	1230
a.	Rationale for and Procedures of the Original OTC Drug Review .....	1230

	Over-the-Counter Drugs: Proposal Establishing Rule Making Procedures for Classification .....	1231
	Elizabeth Guo, Richard Kingham, & David Spangler, <i>An Unofficial Legislative History of Over-the-Counter Monograph Reform</i> .....	1232
	Notes .....	1235
	b. Modernization of the OTC Drug Review.....	1239
	Over-the-Counter Drug Monograph System—Past, Present, and Future; Public Hearing .....	1239
	Note .....	1241
4.	OTC Drug Labeling and Advertising.....	1242
	a. OTC Drug Review Restrictions .....	1242
	Labeling of Drug Products for Over-the-Counter Human Use .....	1242
	Notes .....	1243
	b. OTC “Drug Facts”.....	1244
	Over-the-Counter Human Drugs; Proposed Labeling Requirements.....	1244
	c. OTC Drug Label Warnings.....	1246
	Notes .....	1247
	d. FTC Regulation of OTC Drug Advertising .....	1247
	Notes .....	1249
5.	OTC Drug Product Packaging.....	1249
	Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug and Cosmetic Products .....	1250
	Notes .....	1251
J.	Generic Drugs .....	1253
	1. Generic Drugs Before the Hatch-Waxman Amendments (1984) .....	1253
	a. Copies of Pre-1962 Drugs .....	1253
	Hoffmann-LaRoche, Inc. v. Weinberger.....	1254
	Note .....	1256
	b. Copies of Post-1962 Drugs .....	1256
	Note .....	1258
	United States v. Generix Drug Corp.....	1258
	2. The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Amendments) of 1984 .....	1261
	a. Enactment of the Hatch-Waxman Framework .....	1261
	Notes .....	1263
	b. Abbreviated Applications.....	1264
	Notes .....	1264
	i. The ANDA.....	1265
	Note .....	1266
	(a) Sameness.....	1266
	Serono Laboratories, Inc. v. Shalala .....	1266
	Notes.....	1270
	(b) Bioequivalence .....	1272
	Notes.....	1273

ii.	The 505(b)(2) Application.....	1274
	Notes.....	1275
c.	Timing of Approval.....	1275
i.	Patent Term Restoration .....	1276
	Notes.....	1277
ii.	Patent Litigation .....	1279
	Notes.....	1281
iii.	Statutory Exclusivity .....	1284
	Notes.....	1284
3.	The Orange Book and the Multisource Marketplace .....	1289
	Note.....	1291
K.	Innovation and Access Issues.....	1292
1.	Additional Incentives for Innovation .....	1293
a.	Orphan Drug Exclusivity.....	1293
	Genentech, Inc. v. Bowen.....	1294
	Notes .....	1299
	Marlene E. Haffner, <i>Adopting Orphan Drugs—Two</i> <i>Dozen Years of Treating Rare Diseases</i> .....	1301
	Notes .....	1303
b.	Pediatric Exclusivity.....	1304
	Notes .....	1305
c.	Antibiotic Exclusivity.....	1306
	(FDA) Report to Congress: Generating Antibiotic Incentives Now .....	1306
	Notes .....	1308
d.	Tropical Diseases, Rare Pediatric Diseases, and Medical Countermeasure Priority Review Vouchers .....	1308
	Notes .....	1309
2.	Addressing Affordability.....	1309
a.	Concerns About Drug Prices.....	1309
	Notes .....	1313
b.	Encouraging Development and Uptake of Generic Drugs.....	1314
	FDA Tackles Drug Competition to Improve Patient Access .....	1315
	Guidance for Industry: Competitive Generic Therapies....	1316
	Note .....	1317
c.	Recent Controversies .....	1317
	FTC v. Actavis, Inc. ....	1318
	Note .....	1324
	New York ex rel. Schneiderman v. Actavis PLC .....	1325
	Notes .....	1331
3.	Protecting the Supply of Drugs .....	1333
a.	Drug Shortages.....	1333
	Drug Shortages: Root Causes and Potential Solutions: A Report by the Drug Shortages Task Force.....	1333
	Note .....	1337

b.	Supply Chain Security: Counterfeit and Diverted Drugs.....	1337
	Notes .....	1340
L.	FDA Regulation and State Tort Law.....	1342
1.	Failure to Warn: Learned Intermediary Doctrine and Exceptions.....	1342
	MacDonald v. Ortho Pharmaceutical Corporation .....	1343
	Notes .....	1348
2.	Federal Preemption .....	1348
	Wyeth v. Levine.....	1348
	Note.....	1361
	PLIVA, Inc. v. Mensing.....	1361
	Notes .....	1371
	<b>Chapter 7. Food and Drugs for Animals.....</b>	<b>1375</b>
A.	Introduction.....	1375
	Notes .....	1375
B.	Animal Food and Feed.....	1375
	Notes .....	1376
1.	Pet Food.....	1377
	United States v. Sally Miller, Stephen S. Miller, and ChemNutra, Inc.....	1377
	Notes .....	1379
2.	Livestock Feed and the Mad Cow Disease Crisis .....	1381
	Substances Prohibited From Use in Animal Food or Feed .....	1382
	Notes .....	1384
C.	Animal Drugs .....	1386
1.	New Animal Drug Approval .....	1386
	Animal Drug Amendments.....	1386
	Eugene I. Lambert, <i>The Reformation of Animal Drug Law:         The Impact of 1996</i> .....	1388
	Notes .....	1391
2.	The Effectiveness Standard.....	1393
3.	The Safety Standard .....	1394
	Notes .....	1395
4.	Prescription Status and Veterinary Feed Directives.....	1396
	a. Prescription Animal Drugs.....	1396
	b. Veterinary Feed Directive Drugs .....	1397
	Note.....	1398
5.	Extra-Label Use of Animal Drugs and Use of Human Drugs in Animals .....	1398
	a. Extra-Label Use of Animal Drugs in Animals .....	1398
	Takhar v. Kessler .....	1399
	United States v. Scenic View Dairy, L.L.C.....	1401
	Notes .....	1404
	b. Extra-Label Use of Human Drugs in Animals .....	1405
6.	Animal Drugs for Minor Use and Minor Species .....	1406
	FDA, Minor Use/Minor Species.....	1406
	a. Conditional Approval .....	1407

b.	Indexing .....	1407
c.	Designation .....	1408
d.	Noneforcement Discretion for Extra-Label/Unapproved Use .....	1408
7.	Animal Drug Compounding .....	1409
	United States v. Franck's Lab, Inc. ....	1409
	Notes .....	1411
8.	The Safety of Antibiotics Used in Livestock Production .....	1412
	Harold C. Hopkins, <i>Keeping the Kick in Antibiotics</i> .....	1412
	Antibiotic and Sulfonamide Drugs in the Feed of Animals .....	1413
	Natural Resources Defense Council, Inc. v. Food and Drug Administration .....	1416
	Guidance for Industry: The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals .....	1421
	Notes .....	1423
	Natural Resources Defense Council v. Food and Drug Administration .....	1424
	Withdrawal of Approval of the New Animal Drug Application for Enrofloxacin in Poultry: Final Decision of the Commissioner .....	1426
	Notes .....	1432
9.	Bioengineered Animals .....	1432
	CVM Draft Guidance for Industry No. 187, Regulation of Intentionally Altered Genomic DNA in Animals .....	1433
	Notes .....	1435
	Institute for Fisheries Resources v. FDA .....	1437
10.	Xenotransplantation .....	1438
	Roni Caryn Raybin, <i>Breakthrough on Pig Organs in     Transplants</i> .....	1439

## **Chapter 8. Biological Products .....** 1441

A.	Historical Background .....	1441
1.	Early Biologics Regulation .....	1441
	Notes .....	1443
2.	FDA Acquires Responsibility for Biologics .....	1443
	Note .....	1446
3.	The Biologics Review (Pre-1972 Biologics) .....	1446
	Biological Products: Procedures for Review of Safety, Effectiveness, and Labeling .....	1447
	Reclassification Procedures to Determine That Licensed Biological Products are Safe, Effective, and Not Misbranded Under Prescribed, Recommended, or Suggested Conditions of Use; Proposed Revision .....	1449
	Notes .....	1451
	Licensing; Reclassification Procedures To Determine That Licensed Biological Products Are Safe, Effective, and Not Misbranded Under Prescribed, Recommended or Suggested Conditions of Use .....	1452

	Notes .....	1454
4.	The Modern Era .....	1455
	Reinventing Regulation of Drugs Made From Biotechnology ...	1457
	Elimination of Establishment License Application for Specified Biotechnology and Specified Synthetic Biological Products .....	1457
	Biological Products Regulated Under Section 351 of the Public Health Service Act; Implementation of Biologics License; Elimination of Establishment License and Product License .....	1459
	Transfer of Therapeutic Products to the Center for Drug Evaluation and Research (CDER) .....	1460
	Notes .....	1461
B.	Therapeutic Biologics Regulated by CDER .....	1463
1.	The Biologics License Application .....	1463
	Note .....	1465
2.	The Biosimilar Application .....	1466
a.	Development and Approval of a Biosimilar Biological Product .....	1468
	Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product .....	1468
	Notes .....	1472
b.	Demonstrating Interchangeability .....	1473
	Guidance for Industry: Considerations in Demonstrating Interchangeability With a Reference Product .....	1474
	Notes .....	1475
c.	Naming and Labeling of Biological Products, Including Biosimilar Biologics .....	1475
i.	Naming .....	1475
	Guidance for Industry: Nonproprietary Naming of Biological Products .....	1476
	Note .....	1478
ii.	Labeling .....	1478
	Notes .....	1479
d.	Exclusivity and Patents .....	1479
i.	Exclusivity Provisions .....	1480
	Notes .....	1481
ii.	Patent Litigation .....	1482
	Sandoz v. Amgen .....	1483
	Notes .....	1487
C.	Vaccines .....	1489
	Notes .....	1490
1.	Premarket Development and Licensure .....	1490
	Notes .....	1491
2.	Postmarket Regulation .....	1493
	Note .....	1494

3.	The Fragility of the U.S. Vaccine Supply .....	1494
	Paul Offit, <i>The Cutter Incident: How America's First Polio</i> Vaccine Led to the Growing Vaccine Crisis .....	1494
	Gottsdanker v. Cutter Laboratories.....	1496
	Reyes v. Wyeth Laboratories.....	1499
	Note.....	1504
	Berkovitz v. United States .....	1505
	Note.....	1509
	Institute of Medicine, <i>Financing Vaccines in the 21st</i> Century: Assuring Access and Availability .....	1510
4.	Policy Solutions .....	1512
	Michael Greenberger, <i>The 800 Pound Gorilla Sleeps: The</i> <i>Federal Government's Lackadaisical Liability and</i> <i>Compensation Policies in the Context of Pre-Event</i> <i>Vaccine Immunization Programs</i> .....	1512
	Notes .....	1516
	Note.....	1517
D.	Blood and Blood Products.....	1518
1.	History of FDA Jurisdiction .....	1518
2.	The Regulatory Mechanism.....	1520
	Notes .....	1521
3.	Protecting the Safety of the Blood Supply.....	1523
	Adequacy of the National Blood Supply: Report to Congress.....	1523
	Note.....	1526
a.	The Five Layers of Blood Safety.....	1526
	Keeping Blood Transfusions Safe: FDA's Multi-Layered Protections for Donated Blood .....	1526
b.	Testing Blood and Screening Donors .....	1528
	Snyder v. American Association of Blood Banks.....	1528
	R.F. and R.F. v. Abbott Laboratories .....	1535
	Note .....	1539
	Guidance: Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products .....	1539
	Notes .....	1543
E.	Regenerative Medicine .....	1544
1.	Whole Organ Transplants .....	1544
	Statement by the Food and Drug Administration Concerning Its Legal Authority to Regulate Human Organ Transplants and to Prohibit Their Sale.....	1545
	Note.....	1547
2.	Human Cell-Based and Tissue-Based Products: Part 1271 .....	1547
a.	Historical Background .....	1547
	Richard A. Merrill, <i>Human Tissues and Reproductive</i> <i>Cloning: New Technologies Challenge FDA</i> .....	1548
	Note .....	1553

b.	Regulation Under Part 1271 .....	1553
	Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing....	1554
	Notes .....	1555
c.	Identifying Products Regulated Only Under Part 1271 ....	1556
	Guidance: Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use .....	1556
	Notes .....	1559
3.	Cellular and Gene Therapy Products Subject to Licensure .....	1560
a.	Stem Cell Therapies .....	1560
	Peter W. Marks, Celia M. Witten, and Robert M. Califf, <i>Clarifying Stem- Cell Therapy's Benefits and     Risks</i> .....	1561
	United States v. Regenerative Sciences, LLC .....	1563
	Note .....	1568
b.	(Somatic) Cell Therapy Products .....	1568
	Note .....	1569
c.	Gene Therapy Products .....	1569
	Francis Collins and Scott Gottlieb, <i>The Next Phase of     Human Gene-Therapy Oversight</i> .....	1569
	Note .....	1572
	Note .....	1574
d.	Xenotransplantation Products .....	1574
	Guidance: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans .....	1574
4.	(Human) Reproductive Cloning.....	1577
	Richard A. Merrill, <i>Human Tissues and Reproductive     Cloning: New Technologies Challenge FDA</i> .....	1577
	FDA's Jurisdiction Over Human Cloning Activities.....	1580
	Richard A. Merrill, <i>Human Tissues and Reproductive     Cloning: New Technologies Challenge FDA</i> .....	1582
	Notes .....	1583
5.	The Regenerative Medicine Framework.....	1584
F.	Other Biological Products.....	1585
	<b>Chapter 9. Medical Devices .....</b>	<b>1587</b>
A.	Introduction.....	1587
	Wallace F. Janssen, <i>The Gadgeteers</i> .....	1587
	Note.....	1588
B.	Regulation of Devices Under the FD&C Act Before 1976 .....	1588
1.	The 1938 Framework .....	1589
	Medical Device Legislation—1975 .....	1589
2.	Diapulse Litigation .....	1590
3.	Scientology's E-Meter .....	1591
	Founding Church of Scientology v. United States .....	1591
	Notes .....	1593
4.	Distinguishing Drugs from Devices Before 1976 .....	1595



C.	The Medical Device Amendments of 1976.....	1597
1.	The Need for Legislation .....	1597
	Medical Device Amendments of 1976 .....	1597
	Study Group on Medical Devices, Medical Devices: A Legislative Plan.....	1598
	Notes .....	1598
2.	Overview of the Modern Regime .....	1599
3.	Defining “Device” .....	1600
a.	The Line Between a “Drug” and a “Device” .....	1600
	Genus Medical Technologies LLC v. Food and Drug Administration.....	1602
	Note .....	1610
b.	Drug-Device Combinations.....	1610
	PREVOR v. Food and Drug Administration.....	1611
	Notes .....	1616
c.	Diagnostic Devices .....	1617
D.	Classification of Devices into Class I, Class II, or Class III.....	1618
1.	Classification Procedures .....	1618
	Medical Devices: Classification Procedures .....	1618
	Note.....	1619
2.	The Classification Regulations.....	1619
	21 C.F.R. Part 872—Dental Devices.....	1620
	Notes .....	1621
E.	Changeover Issues: Regulating Pre-1976 Devices Under the 1976 Amendments .....	1621
1.	Equitable Treatment of Old and New Devices.....	1621
2.	Reviewing Preamendment Class III Devices .....	1622
3.	“Transitional” Devices Previously Regulated as Drugs.....	1624
F.	Regulation of Market Entry .....	1625
1.	Premarket Notification via the 510(k) Process .....	1627
a.	Background.....	1627
b.	“Substantial Equivalence” .....	1627
c.	“Piggybacking”.....	1628
d.	Exemptions from the 510(k) Requirement .....	1629
e.	Revoking a 510(k) Clearance.....	1630
	Ivy Sports Medicine, LLC v. Burwell.....	1630
	Notes .....	1637
f.	Modified 510(k) Pathways .....	1638
	Notes .....	1638
g.	Reprocessed Single-Use Devices .....	1642
2.	Investigational Devices.....	1643
a.	General Requirements .....	1643
b.	Feasibility Studies.....	1644
c.	“Research Use Only” Exemption for Diagnostic Devices .....	1645
	Notes .....	1645
d.	Emergency Investigational Use .....	1646
	Cristine Russell, <i>Temporary Heart Implanted: Tucson Operation Lacked FDA Approval</i> .....	1647

	Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors: Frequently Asked Questions About Medical Devices .....	1648
e.	Emergency Use Authorizations .....	1649
	Guidance for Developers and FDA Staff: Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised).....	1650
	Notes .....	1653
3.	Premarket Approval (PMA) Applications .....	1654
a.	Comparing PMAs and NDAs .....	1654
	Notes .....	1656
b.	Advisory Committee Review.....	1657
c.	FDA Action on PMAs .....	1658
	Notes .....	1659
d.	Efforts to Quicken PMA Reviews .....	1660
	Notes .....	1661
e.	Postapproval PMA Requirements .....	1662
4.	Shortcuts and Exemptions .....	1663
a.	Breakthrough Devices.....	1663
	Note .....	1664
b.	In Vitro Diagnostics .....	1664
c.	Humanitarian Device Exemptions.....	1669
	Note .....	1670
d.	Custom Devices .....	1670
	Note .....	1671
5.	Reclassification and De Novo Classification .....	1671
	Lake v. FDA.....	1673
	Notes .....	1675
G.	Postmarket Regulation of Devices .....	1676
1.	General Controls Applicable to All Devices .....	1676
a.	Adulteration and Misbranding.....	1676
	United States v. An Article . . . Acu-dot.....	1677
	Medical Devices; Labeling for Menstrual Tampons; Ranges of Absorbency; Reproposed Rule .....	1680
	Note .....	1681
b.	Establishment Registration and Product Listing .....	1682
c.	Adverse Event Reporting.....	1682
d.	Good Manufacturing Practice (Quality Systems Regulation) .....	1684
	Medical Devices; Current Good Manufacturing Practice (CGMP) Regulations; Proposed Revisions; Request for Comments .....	1685
	Notes .....	1686
e.	Restricted Devices .....	1688
i.	Introduction .....	1688
ii.	Hearing Aids.....	1689
	American Speech and Hearing Ass'n v. Califano .....	1690
	Note .....	1691
iii.	In Vitro Diagnostic Devices .....	1691

iv.	Cigarettes.....	1693
	Coyne Beahm, Inc. v. United States Food & Drug Administration.....	1694
	Notes.....	1696
f.	Banned Devices .....	1696
	Judge Rotenberg Educational Center, Inc. v. FDA.....	1697
	Note .....	1705
g.	Administrative Detention .....	1705
h.	Notification and Repair, Replacement, or Refund .....	1705
	In re Procter & Gamble Co.: Consent Agreement .....	1706
	Notes .....	1706
i.	Postmarket Surveillance.....	1708
j.	Device Tracking.....	1709
k.	Mandatory Recalls.....	1710
l.	Reports of Removals and Corrections .....	1710
m.	Civil Penalties .....	1711
2.	Special Controls for Class II Devices .....	1712
a.	Performance Standards .....	1712
	i. Introduction .....	1712
	ii. Voluntary Medical Device Standards.....	1713
b.	Other Special Controls.....	1715
H.	Digital Health Devices.....	1715
1.	History .....	1717
	Nathan Cortez, <i>Analog Agency in a Digital World</i> .....	1717
	Notes .....	1723
2.	Current Framework .....	1724
a.	The Scope of FDA Jurisdiction over Software .....	1724
	Guidance for Industry and FDA Staff: Policy for Device Software Functions and Mobile Medical Applications .....	1725
	Notes .....	1730
b.	Regulatory Expectations for Software .....	1731
3.	The Digital Health Action Plan.....	1733
a.	Pre-Market to Post-Market Evidence Gathering.....	1734
b.	From Product-Level to Firm-Level Oversight.....	1735
c.	Third-Party Reviews .....	1736
	Notes .....	1736
I.	Radiation Control.....	1737
1.	Performance Standards .....	1737
	Electronic Products; Performance Standard for Diagnostic X-Ray Systems and Their Major Components (Final Rule).....	1738
	Notes .....	1739
	Sunlamp Products; Performance Standard .....	1741
	Notes .....	1742
2.	Enforcement of Radiation Standards.....	1743
3.	Collection and Dissemination of Information .....	1744
4.	Other Federal Radiation Control Programs.....	1745

J.	Preemption of State Law .....	1746
1.	Preemption Under the 1976 Medical Device Amendments .....	1746
	Exemptions From Federal Preemption of State and Local Device Requirements .....	1747
	Notes .....	1748
2.	Medtronic v. Lohr .....	1748
	Medtronic, Inc. v. Lohr .....	1749
	Notes .....	1756
3.	Riegel v. Medtronic .....	1757
	Riegel v. Medtronic, Inc. ....	1757
	Notes .....	1760
<b>Chapter 10. Cosmetics.....</b>		<b>1763</b>
A.	Historical and Statutory Background .....	1763
	Peter Barton Hutt, <i>A History of Government Regulation of   Adulteration and Misbranding of Cosmetics</i> .....	1763
	Personal Care Products Council, <i>Driving the Economy, Shaping   the Future</i> .....	1764
	Senate Report No. 361 .....	1765
	Notes .....	1766
	George P. Larrick, <i>Some Current Problems in the Regulation of   Cosmetics Under the Federal Food, Drug, and Cosmetic Act</i> ....	1766
	Investigation of the Use of Chemicals in Foods and Cosmetics.....	1767
	S. L. Mayham, <i>Chemicals in Cosmetics</i> .....	1769
	U.S. General Accounting Office, <i>Lack of Authority Hampers   Attempts to Increase Cosmetic Safety</i> .....	1770
	Statement of the Cosmetic, Toiletry and Fragrance Association, Inc.....	1772
	Notes .....	1774
B.	Definition of “Cosmetic” .....	1775
C.	Adulterated Cosmetics .....	1775
	United States v. An Article of Cosmetic . . . “Beacon Castile Shampoo” .....	1775
	Notes .....	1777
	Aerosol Drug and Cosmetic Products Containing Zirconium .....	1779
	Notes .....	1780
	Nitrosamine-Contaminated Cosmetics; Call for Industry Action; Request for Data .....	1782
	Notes .....	1782
D.	Coal-Tar Hair Dyes .....	1787
	Toilet Goods Association v. Finch .....	1787
	Notes .....	1789
E.	The Scope of the Color Additive Amendments.....	1790
F.	Misbranded Cosmetics.....	1790
1.	Label Warnings .....	1790
	Preservation of Cosmetics Coming in Contact With the Eye: Intent to Propose Regulations and Request for Information .....	1790
	Notes .....	1791

	Food, Drug, and Cosmetic Products: Warning Statements.....	1792
	Notes .....	1795
2.	Misleading Labeling.....	1796
	Almay, Inc. v. Califano.....	1796
	Note.....	1798
	Peter Barton Hutt, <i>The Legal Distinction in the United States Between a Cosmetic and a Drug</i> .....	1799
	Notes .....	1800
G.	Cosmetic Ingredient Labeling .....	1801
	Cosmetic Ingredient Labeling .....	1801
	Notes .....	1802
H.	Voluntary Self-Regulation of Cosmetics.....	1804
	Voluntary Registration of Cosmetic Product Establishments; Voluntary Filing of Cosmetic Product Ingredient and Cosmetic Raw Material Composition Statements .....	1805
	Voluntary Filing of Cosmetic Product Experiences .....	1805
	Notes .....	1806
	Robert L. Elder, <i>The Cosmetic Ingredient Review—A Safety Evaluation Program</i> .....	1808
	Statement of Robert L. Elder, SC.D. ....	1810
	Wilma F. Bergfeld et al., <i>Safety of Ingredients Used in Cosmetics</i> .....	1811
	Letter From Ronald G. Chesemore, Associate Commissioner for Regulatory Affairs, FDA, to Consumer Federation of America .....	1812
	Note.....	1813
	Letter From Robert E. Brackett, Director, FDA Center for Food Safety and Applied Nutrition, to CTFA.....	1813
	Notes .....	1814
I.	The Present and Future of Cosmetics Regulation .....	1815
	Peter Barton Hutt, “Examining the Current State of Cosmetics” ....	1815
J.	The Draft Modernization of Cosmetics Regulation Act of 2022.....	1817
<b>Chapter 11. Tobacco Products .....</b>		<b>1819</b>
A.	Introduction.....	1819
B.	Efforts to Regulate Tobacco Products Under the FD&C Act Before 2009.....	1820
	Food and Drug Administration v. Brown & Williamson Tobacco Corp.....	1822
C.	The Family Smoking Prevention and Tobacco Control Act .....	1827
1.	The Line Between Tobacco Products and Drugs and Devices .....	1828
	Sottera, Inc. v. FDA .....	1829
	21 C.F.R. § 1100.5. Exclusion from Tobacco Regulation .....	1833
	Notes .....	1834
2.	“Deemed” Products.....	1835
	Nicopure Labs, LLC v. FDA .....	1837
	Notes .....	1839

3.	Comprehensive Plan for Tobacco and Nicotine Regulation .....	1842
	Speech by Scott Gottlieb, M.D., “Protecting American Families: Comprehensive Approach to Nicotine and Tobacco” .....	1843
	Notes .....	1845
D.	Tobacco Product Review .....	1847
1.	Substantial Equivalence (SE) Reports .....	1848
	Content and Format of Substantial Equivalence Reports (Final Rule) .....	1849
	Notes .....	1851
2.	Exemptions from Demonstrating Substantial Equivalence (SE).....	1852
3.	Premarket Tobacco Product Applications (PMTAs) .....	1853
	21 C.F.R. § 1114.7. Required Content and Format.....	1854
	Notes .....	1855
4.	Modified Risk Tobacco Product (MRTP) Application.....	1856
a.	Products Subject to MRTP Application Requirements .....	1856
	Letter From Lawrence R. Deyton, Dir., Center for Tobacco Products, to Tobacco Manufacturers on Tobacco Products Labeled or Advertised With the Descriptors “Light,” “Low,” “Mild,” or Similar Descriptors .....	1857
	Notes .....	1858
b.	FDA Review of MRTP Applications .....	1858
	Scientific Standards for Studies on Modified Risk Tobacco Products .....	1860
	Notes .....	1861
E.	Tobacco Product Restrictions .....	1862
	Cigar Ass’n of Am. v. United States Food & Drug Admin. ....	1863
F.	Tobacco Product Standards .....	1865
	Letter from May D. Nelson, Director, Office of Regulations, CTP, FDA to D. Douglas Blanke, Public Health Law Center .....	1866
	Notes .....	1869
G.	Graphic Warnings for Cigarettes .....	1870
	Discount Tobacco City & Lottery, Inc. v. United States .....	1871
	Notes .....	1873
	R.J. Reynolds Tobacco Co. v. Food & Drug Administration.....	1874
	Tobacco Products: Required Warnings for Cigarette Packages and Advertisements (Final Rule) .....	1879
	Note.....	1882
	<b>Chapter 12. Regulation of Carcinogens.....</b>	<b>1883</b>
A.	Historical Background.....	1883
B.	Early FDA Policy .....	1884
	Arnold Lehman et al., <i>Procedures for the Appraisal of the Toxicity     of Chemicals in Foods</i> .....	1884
	Notes .....	1884
C.	Evolution of Legislative Policy .....	1885
1.	The Food Additive Delaney Clause .....	1885

2.	The Color Additive Delaney Clause .....	1887
3.	The Animal Drug Delaney Clause and the “DES Proviso” .....	1889
	Diethylstilbestrol: Withdrawal of Approval of New Animal Drug Application .....	1890
	Notes .....	1891
D.	FDA Embraces Quantitative Risk Assessment .....	1891
1.	Applied to Animal Drugs (the “DES Proviso”) .....	1892
	Chemical Compounds in Food-Producing Animals: Criteria and Procedures for Evaluating Assays for Carcinogenic Residues in Edible Products of Animals .....	1894
	Notes .....	1900
	Sponsored Compounds in Food-Producing Animals; Criteria and Procedures for Evaluating the Safety of Carcinogenic Residues .....	1901
	Notes .....	1902
2.	Applied to Contaminants of Food.....	1903
	Aflatoxins in Shelled Peanuts and Peanut Products Used as Human Foods: Proposed Tolerance .....	1903
	Notes .....	1903
3.	Applied to “Constituents” of Additives .....	1905
	Policy for Regulating Carcinogenic Chemicals in Food and Color Additives: Advance Notice of Proposed Rulemaking.....	1905
	Scott v. Food and Drug Administration.....	1907
	Notes .....	1908
4.	Applied to Direct Additives .....	1909
a.	Artificial Sweeteners in Food .....	1909
	Notes .....	1910
b.	Color Additive in Hair Dye .....	1911
	Lead Acetate; Listing as a Color Additive in Cosmetics That Color the Hair on the Scalp .....	1911
	Notes .....	1912
c.	Color Additive (Orange No. 17) in Externally Applied Drugs and Cosmetics.....	1913
	Listing of D&C Orange No. 17 for Use in Externally Applied Drugs and Cosmetics.....	1913
	Correction of Listing of D&C Orange No. 17 for Use in Externally Applied Drugs and Cosmetics.....	1914
	Public Citizen v. Young.....	1914
	Notes .....	1917
5.	Applied to Natural Food .....	1918
6.	Summary of Applications to Food .....	1920
7.	Applied to Drugs .....	1921
8.	Administrative Review and Decision on Carcinogens and Risk Assessment.....	1922
E.	Deciding Whether an Additive “Induces Cancer” .....	1922
1.	Carcinogenicity Thresholds .....	1922
	Selenium in Animal Feed; Proposed Food Additive Regulation.....	1923

	Notes .....	1924
2.	FDA Scientific Assessment.....	1925
	Notes .....	1930
F.	Resolving the “Delaney Paradox” for Food Pesticides .....	1931
	Les v. Reilly .....	1932
	James Smart, <i>All the Stars in the Heavens Were in the Right Places: The Passage of the Food Quality Protection Act of 1996</i> .....	1934
	Allison D. Carpenter, <i>Impact of the Food Quality Protection Act of 1996</i> .....	1935
	Notes .....	1936
G.	Other Efforts to Identify or Regulate Carcinogens.....	1937
	1. IARC and NTP .....	1937
	2. Other Federal Agency Cancer Regulation.....	1938
	a. The Environmental Protection Agency.....	1938
	b. The Occupational Safety and Health Administration .....	1939
	c. The Consumer Product Safety Commission .....	1940
	3. Government-Wide Policies .....	1941
H.	The Limits of Regulating Carcinogens .....	1942
	1. Reduction or Elimination of Cancer Would Have a Small Impact on Human Lifespan.....	1942
	Peter Barton Hutt, <i>Food and Drug Law: A Strong and Continuing Tradition</i> .....	1942
	Notes .....	1943
	2. California Proposition 65.....	1945
	3. The First Amendment Limitations on Cancer Warnings.....	1946
	National Association of Wheat Growers v. Zeise .....	1946
	INDEX .....	1951